Associations of tumor suppressor SPARCL1 with cancer progression and prognosis (Review)

Li,Ting; Liu,Xia; Yang,Antai; Fu,Wenjie; Yin,Fuqiang; Zeng,Xiaoyun

doi:10.3892/ol.2017.6546

Associations of tumor suppressor SPARCL1 with cancer progression and prognosis (Review)

Authors:
- Ting Li
- Xia Liu
- Antai Yang
- Wenjie Fu
- Fuqiang Yin
- Xiaoyun Zeng
View Affiliations

Affiliations: Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Centre for Translational Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Key Laboratory of High‑Incidence‑Tumor Prevention and Treatment, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: July 8, 2017 https://doi.org/10.3892/ol.2017.6546
Pages: 2603-2610
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SPARC‑like protein 1 (SPARCL1), a member of the family of secreted proteins which is acidic and rich in cysteine, is a potential tumor suppressor gene in most types of tumor. A systemic review and bioinformatics analysis was carried out to determine the associations between SPARCL1 and tumor progression and clinical factors. Downregulation of SPARCL1, thought to be regulated by epigenetic modifications including DNA methylation, serves important functions in tumor progression and development, with its regulatory functions on cell viability, migration, invasion, cell adhesion and drug resistance. Downregulation of SPARCL1 was markedly associated with a poor overall survival rate of patients with one of ≥7 solid tumors and predicted increased mortality in patients with one of ≥4 distinct tumor types. The present review indicated that SPARCL1 may be a therapeutic target for cancer treatment and a biomarker to determine prognosis.

View Figures

View References

1	Johnston IG, Paladino T, Gurd JW and Brown IR: Molecular cloning of SC1: A putative brain extracellular matrix glycoprotein showing partial similarity to osteonectin/BM40/SPARC. Neuron. 4:165–176. 1990. View Article : Google Scholar : PubMed/NCBI
2	Schraml P, Shipman R, Stulz P and Ludwig CU: cDNA subtraction library construction using a magnet-assisted subtraction technique (MAST). Trends Genet. 9:70–71. 1993. View Article : Google Scholar : PubMed/NCBI
3	Girard JP and Springer TA: Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity. 2:113–123. 1995. View Article : Google Scholar : PubMed/NCBI
4	Claeskens A, Ongenae N, Neefs JM, Cheyns P, Kaijen P, Cools M and Kutoh E: Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer. 82:1123–1130. 2000. View Article : Google Scholar : PubMed/NCBI
5	Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC and Motamed K: Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia. 11:126–135. 2009. View Article : Google Scholar : PubMed/NCBI
6	Tai IT, Dai M, Owen DA and Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest. 115:1492–1502. 2005. View Article : Google Scholar : PubMed/NCBI
7	Lau CP, Poon RT, Cheung ST, Yu WC and Fan ST: SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol. 210:459–468. 2006. View Article : Google Scholar : PubMed/NCBI
8	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T and Pandey A: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
9	Schlomm T, Luebke AM, Sültmann H, Hellwinkel OJ, Sauer U, Poustka A, David KA, Chun FK, Haese A, Graefen M, et al: Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. Int J Oncol. 27:713–720. 2005.PubMed/NCBI
10	Isler SG, Ludwig CU, Chiquet-Ehrismann R and Schenk S: Evidence for transcriptional repression of SPARC-like 1, a gene downregulated in human lung tumors. Int J Oncol. 25:1073–1079. 2004.PubMed/NCBI
11	Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, O'Dwyer PJ, Livolsi VA and Johnson SW: Gene expression profiling of human ovarian tumours. Br J Cancer. 95:1092–1100. 2006. View Article : Google Scholar : PubMed/NCBI
12	Esposito I, Kayed H, Keleg S, Giese T, Sage EH, Schirmacher P, Friess H and Kleeff J: Tumor-suppressor function of SPARC-like protein 1/hevin in pancreatic cancer. Neoplasia. 9:8–17. 2007. View Article : Google Scholar : PubMed/NCBI
13	Hu H, Zhang H, Ge W, Liu X, Loera S, Chu P, Chen H, Peng J, Zhou L, Yu S, et al: Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. Clin Cancer Res. 18:5438–5448. 2012. View Article : Google Scholar : PubMed/NCBI
14	Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, et al: SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol. 7:1019–1030. 2013. View Article : Google Scholar : PubMed/NCBI
15	Yu Y, Chen Y, Ma J, Yu X, Yu G and Li Z: SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma. Tumour Biol. 37:4159–4167. 2016. View Article : Google Scholar : PubMed/NCBI
16	Turtoi A, Musmeci D, Naccarato AG, Scatena C, Ortenzi V, Kiss R, Murtas D, Patsos G, Mazzucchelli G, De Pauw E, et al: Sparc-like protein 1 is a new marker of human glioma progression. J Proteome Res. 11:5011–5021. 2012. View Article : Google Scholar : PubMed/NCBI
17	Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, et al: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 65:1748–1754. 2005. View Article : Google Scholar : PubMed/NCBI
18	Yin F, Liu X, Li D, Wang Q, Zhang W and Li L: Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer. Int J Oncol. 42:1305–1316. 2013.PubMed/NCBI
19	Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, et al: Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci USA. 109:14977–14982. 2012. View Article : Google Scholar : PubMed/NCBI
20	Hurley PJ, Hughes RM, Simons BW, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kimura Y, Jabbari J, et al: Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Res. 75:4322–4334. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhang H, Widegren E, Wang DW and Sun XF: SPARCL1: A potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer. Tumour Biol. 32:1225–1231. 2011. View Article : Google Scholar : PubMed/NCBI
22	Jakharia A, Borkakoty B and Singh S: Expression of SPARC like protein 1 (SPARCL1), extracellular matrix-associated protein is down regulated in gastric adenocarcinoma. J Gastrointest Oncol. 7:278–283. 2016.PubMed/NCBI
23	Li P, Qian J, Yu G, Chen Y, Liu K, Li J and Wang J: Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol. 105:31–37. 2012. View Article : Google Scholar : PubMed/NCBI
24	Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
25	Sato T, Arai E, Kohno T, Takahashi Y, Miyata S, Tsuta K, Watanabe S, Soejima K, Betsuyaku T and Kanai Y: Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease. Int J Cancer. 135:319–334. 2014. View Article : Google Scholar : PubMed/NCBI
26	Mencalha AL, Levinsphul A, Deterling LC, Pizzatti L and Abdelhay E: SPARC-like1 mRNA is overexpressed in human uterine leiomyoma. Mol Med Rep. 1:571–574. 2008.PubMed/NCBI
27	Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y and Zheng S: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol. 17:2028–2036. 2011. View Article : Google Scholar : PubMed/NCBI
28	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
29	Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, et al: ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst. 106:pii: dju149. 2014. View Article : Google Scholar : PubMed/NCBI
30	Gyorffy B, Lánczky A and Szállási Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012. View Article : Google Scholar : PubMed/NCBI